Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Mologni

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Translational Lung Cancer Research|March 26, 2015
Expanding the portfolio of anti-ALK weaponsLuca Mologni
World Journal of Clinical Oncology|October 16, 2015
Current and future treatment of anaplastic lymphoma kinase-rearranged cancerLuca Mologni
Expert Opinion on Investigational Drugs|May 23, 2012
Inhibitors of the anaplastic lymphoma kinaseLuca Mologni
Endocrine-Related Cancer|January 20, 2018
Novel targeted therapeutics for MEN2Sara Redaelli, Ivan Plaza-Menacho, Luca Mologni
Cancers|January 6, 2021
Dual Kinase Targeting in LeukemiaLuca Mologni, Giovanni Marzaro, Sara Redaelli, et al.
Expert Opinion on Therapeutic Patents|September 21, 2016
RET kinase inhibitors: a review of recent patents (2012-2015)Luca Mologni, Carlo Gambacorti-Passerini, Peter Goekjian, et al.
Biochemical and Biophysical Research Communications|March 9, 2005
Characterization of mouse myotilin and its promoterLuca Mologni, Monica Moza, Maciej M Lalowski, et al.
Plos One|December 11, 2012
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cellsLuca Mologni, Stefania Brussolo, Monica Ceccon, et al.
Cancer Medicine|March 3, 2015
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALKDiletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini, et al.
Chemmedchem|June 23, 2017
Discovery of <sup>wt</sup> RET and <sup>V804M</sup> RET Inhibitors: From Hit to LeadLuca Mologni, Martina Dalla Via, Adriana Chilin, et al.
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Translational Lung Cancer Research|March 26, 2015
Expanding the portfolio of anti-ALK weaponsLuca Mologni
World Journal of Clinical Oncology|October 16, 2015
Current and future treatment of anaplastic lymphoma kinase-rearranged cancerLuca Mologni
Expert Opinion on Investigational Drugs|May 23, 2012
Inhibitors of the anaplastic lymphoma kinaseLuca Mologni
Endocrine-Related Cancer|January 20, 2018
Novel targeted therapeutics for MEN2Sara Redaelli, Ivan Plaza-Menacho, Luca Mologni
Cancers|January 6, 2021
Dual Kinase Targeting in LeukemiaLuca Mologni, Giovanni Marzaro, Sara Redaelli, et al.
Expert Opinion on Therapeutic Patents|September 21, 2016
RET kinase inhibitors: a review of recent patents (2012-2015)Luca Mologni, Carlo Gambacorti-Passerini, Peter Goekjian, et al.
Biochemical and Biophysical Research Communications|March 9, 2005
Characterization of mouse myotilin and its promoterLuca Mologni, Monica Moza, Maciej M Lalowski, et al.
Plos One|December 11, 2012
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cellsLuca Mologni, Stefania Brussolo, Monica Ceccon, et al.
Cancer Medicine|March 3, 2015
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALKDiletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini, et al.
Chemmedchem|June 23, 2017
Discovery of <sup>wt</sup> RET and <sup>V804M</sup> RET Inhibitors: From Hit to LeadLuca Mologni, Martina Dalla Via, Adriana Chilin, et al.
Pageof 9